Introduction to ARIA
Recommended Literature
Considerations for patients with preexisting cerebrovascular disease
Greenberg, S. M., Aparicio, H. J., Furie, K. L., Goyal, M. S., Hinman, J. D., Kozberg, M., Leonard, A., & Fisher, M. J. (2025). Vascular Neurology Considerations for Antiamyloid Immunotherapy: A Science Advisory From the American Heart Association. Stroke, 56(1). https://doi.org/10.1161/STR.0000000000000480
“Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics” Brain. 2023 Jun 6;146(11):4414–4424. doi: 10.1093/brain/awad188
ASNR resources https://www.asnr.org/education-resources/alzheimers-webinar-series/
“Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities” AJNR Am J Neuroradiol. 2025 Jan 8;46(1):24-32. DOI: 10.3174/ajnr.A8469
Comparing ARIA‐E severity scales and effects of treatment management thresholds
Alzheimers Dement 2022;14:e12376. doi: 10.1002/dad2.12376
Appropriate use recommendations
Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., & Salloway, S. (2023). Lecanemab: Appropriate Use Recommendations. The Journal of Prevention of Alzheimer’s Disease, 10(3), 362–377. link
Rabinovici, G. D., Selkoe, D. J., Schindler, S. E., Aisen, P., Apostolova, L. G., Atri, A., Greenberg, S. M., Hendrix, S. B., Petersen, R. C., Weiner, M., Salloway, S., & Cummings, J. (2025). Donanemab: Appropriate use recommendations. The Journal of Prevention of Alzheimer’s Disease, 12(5), 100150. link
Park, K. H., Kim, G. H., Kim, C.-H., Koh, S.-H., Moon, S. Y., Park, Y. H., Seo, S. W., Yoon, B., Lim, J.-S., Kim, B. C., Kim, H.-J., Na, H. R., Shim, Y., Yang, Y., Lee, C.-N., Rhee, H. Y., Jung, S., Jeong, J. H., Choi, H., … Choi, S. H. (2024). Lecanemab: Appropriate Use Recommendations by Korean Dementia Association. Dementia and Neurocognitive Disorders, 23(4), 165. link